Serial circulating tumor DNA (ctDNA) monitoring enabled detection of resistance-associated genomic signatures in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), highlighting the clinical utility of liquid biopsy for real-time molecular surveillance.
Longitudinal ctDNA analysis revealed the emergence of resistance mutations during therapy, reflecting tumor evolution and adaptive mechanisms that drive treatment failure in EGFR-driven lung cancer.
Patients with detectable resistance-associated alterations demonstrated inferior progression-free survival and poorer overall prognosis, emphasizing the prognostic value of ctDNA-based genomic monitoring.
Dynamic changes in ctDNA mutation profiles provided insights into molecular mechanisms of therapeutic resistance, including alterations that may impact targeted therapy effectiveness.
Continuous ctDNA surveillance enables early detection of treatment resistance before clinical or radiologic progression, allowing clinicians to anticipate disease progression.
Integration of longitudinal ctDNA profiling into clinical management may support adaptive treatment strategies, including timely therapy modification or combination treatment approaches.
This liquid biopsy–based monitoring approach strengthens precision oncology in EGFR-mutant NSCLC, improving personalized treatment planning and disease monitoring.
Overall, ctDNA-driven molecular tracking provides a non-invasive, scalable tool for real-time tumor genomics, advancing precision medicine approaches in advanced lung cancer. Read Abstract